Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
- Warmerdam, L.J. (Laurence) van
- Verweij, J. (Jaap)
- Schellens, J.H.M. (Jan)
- Rosing, H. (Hilde)
- Davies, B.E. (Brian)
- Boer-Dennert, M. (Maureen) de
- Maes, R. (Rudolf)
- Beijnen, J.H. (Jos)
Publication date
May 1995
DOI Publisher
Springer Science and Business Media LLC ISSN
0344-5704Abstract
Topotecan is a novel semisynthetic derivative of the anticancer agent camptothecin and inhibits the intranuclear enzyme topoisomerase I. The lactone structure of topotecan, which is in equilibrium with the inactive ringopened hydroxy acid, is essential for this activity. The open form predominates at physiological pH. We performed a pharmacokinetic, study as part of a phase I study in patients with various types of soli
Add to ORKG